A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) (clinicaltrials.gov) - Oct 1, 2026 - P3 | N=436 | Recruiting | Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1
|